Protalix BioTherapeutics Inc
For the period ended Jun 27, 2024. Filed Apr 29, 2024.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 27, 2024 · Filed Apr 29, 2024
Contents
Primary Changes
As part of the proposed amendments to the Existing Plan, we propose to:
Increase the number of shares of common stock reserved for issuance under the Existing Plan by 5,000,000 shares to 17,475,171 shares;
Increase the annual per person limits on the number of shares covered by awards of stock options and stock appreciation rights by 5,000,000 shares to 17,475,171 shares; and
Increase the per person limits on the number of shares covered by awards of restricted stock and restricted stock units intended to be “performance based compensation” by 5,000,000 shares to 17,475,171 shares.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.